Humanigen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HGENQ research report →
Price Chart
About the company
Humanigen, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies that prevent and manage an overactive immune response. At the forefront of its pipeline is lenzilumab, a monoclonal antibody designed to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF) by binding to it.
- CEO
- Cameron Durrant MBA
- IPO
- 2013
- Employees
- 6
- HQ
- Short Hills, NJ, US
Get TickerSpark's AI analysis on HGENQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $23.82K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2716.95%
- Net Margin
- -2793.87%
- ROE
- 199.39%
- ROIC
- 150.73%
- 52W High
- $0.21
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -1.34
- RSI (14)
- 40
- Avg Volume
- 35.33K
No earnings-call transcripts are available for HGENQ yet.
- Free Float
- 92.8%
- Shares Outstanding
- 119.08M
- Float Shares
- 110.49M
Our HGENQ coverage
Recent articles, reports, and earnings notes.
No research on HGENQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HGENQ report →